Want to see IN:SAILIFE full AI Analyst Report?
SAI Life Sciences Ltd. (SAILIFE) AI Stock Analysis
SAI Life Sciences Ltd.
(NSE:SAILIFE)
The score is primarily supported by strong fundamental momentum (rapid revenue growth, improving margins/ROE, and low leverage) and solid bullish technicals (price above key moving averages with positive MACD). This is meaningfully offset by weak cash conversion (negative free cash flow) and a very expensive valuation (high P/E with no dividend yield provided), which increases downside risk if execution slows.
SAI Life Sciences Ltd. (SAILIFE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 332.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 48.92K
- Price to Earnings (P/E)
- 90.0
- Beta (1Y)
- 0.99
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- India
- Employees
- 5,224
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
SAI Life Sciences Ltd. Business Overview & Revenue Model
Company Description
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The comp...
How the Company Makes Money
SAI Life Sciences makes money by providing fee-based outsourced R&D and manufacturing services to pharmaceutical and biotechnology customers. Its revenue model is typically a mix of (1) discovery and early development services, where customers pay fo...
SAI Life Sciences Ltd. Financial Statement Overview
Summary
Income statement and balance sheet are strong (high growth, expanding margins, improving ROE, and low leverage), but the cash flow profile materially drags the fundamentals due to persistently negative free cash flow despite improved operating cash generation.
Income Statement
86Very PositiveBalance Sheet
84Very PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.79B | 16.96B | 21.92B | 14.56B | 11.97B | 8.69B |
| Gross Profit | 5.89B | 6.19B | 7.72B | 4.88B | 3.18B | 2.67B |
| EBITDA | 4.59B | 4.42B | 6.72B | 3.15B | 1.93B | 1.49B |
| Net Income | 2.33B | 1.70B | 3.49B | 828.09M | 99.89M | 62.26M |
Balance Sheet | ||||||
| Total Assets | 33.32B | 31.60B | 36.26B | 22.75B | 21.87B | 21.64B |
| Cash, Cash Equivalents and Short-Term Investments | 3.06B | 3.72B | 1.58B | 1.85B | 2.05B | 2.16B |
| Total Debt | 5.64B | 3.52B | 2.88B | 9.28B | 9.32B | 9.65B |
| Total Liabilities | 10.62B | 10.32B | 11.42B | 13.00B | 12.99B | 12.86B |
| Stockholders Equity | 22.70B | 21.28B | 24.84B | 9.75B | 8.88B | 8.79B |
Cash Flow | ||||||
| Free Cash Flow | -1.98B | -918.36M | -721.30M | 813.97M | 1.06B | -1.02B |
| Operating Cash Flow | 3.06B | 2.77B | 5.21B | 2.63B | 2.19B | 1.05B |
| Investing Cash Flow | -4.40B | -5.53B | -4.18B | -1.92B | -1.02B | -1.04B |
| Financing Cash Flow | 3.08B | 3.54B | -1.13B | -952.99M | -2.01B | 719.23M |
SAI Life Sciences Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAILIFE, the sentiment is Positive. The current price of 1546.30 is above the 20-day moving average (MA) of 1469.76, above the 50-day MA of 1520.57, and above the 200-day MA of 1205.17, indicating a bullish trend. The MACD of 7.32 indicates Negative momentum. The RSI at 59.31 is Neutral, neither overbought nor oversold. The STOCH value of 84.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SAILIFE.
SAI Life Sciences Ltd. Peers Comparison
Overall Rating
IN:LAURUSLABS77Outperform- IN:SAILIFE70Outperform
IN:NEULANDLAB66Neutral
IN:PPLPHARMA56Neutral
IN:SYNGENE56Neutral
IN:JUBLPHARMA45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:LAURUSLABS | 77Outperform | INR 1.25T | 93.66 | ― | 0.09% | 23.03% | 95.69% |
| IN:SAILIFE | 70Outperform | INR 330.81B | 90.05 | ― | ― | ― | ― |
| IN:NEULANDLAB | 66Neutral | INR 249.35B | 55.50 | ― | 0.17% | 50.46% | 88.44% |
| IN:PPLPHARMA | 56Neutral | INR 311.34B | -150.69 | ― | 0.06% | 9.43% | -767.49% |
| IN:SYNGENE | 56Neutral | INR 164.01B | 90.17 | ― | 0.30% | -5.99% | -60.30% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:JUBLPHARMA | 45Neutral | INR 149.49B | 42.24 | ― | 0.53% | 16.27% | -23.50% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SAILIFE | SAI Life Sciences Ltd. | 1546.30 | 624.20 | 67.69% | |
| IN:JUBLPHARMA | Jubilant Pharmova Limited | 939.45 | -215.92 | -18.69% | |
| IN:LAURUSLABS | Laurus Labs Ltd. | 2306.10 | 1328.12 | 135.80% | |
| IN:NEULANDLAB | Neuland Laboratories Ltd. | 19614.30 | 2093.84 | 11.95% | |
| IN:PPLPHARMA | Piramal Pharma Limited | 237.80 | 38.50 | 19.32% | |
| IN:SYNGENE | Syngene International Ltd. | 417.20 | -201.95 | -32.62% |
SAI Life Sciences Ltd. Corporate Events
Sai Life Sciences Publishes AGM Notice and E‑Voting Details
Sai Life Sciences Limited has notified the stock exchanges that it has published newspaper advertisements announcing its 27th Annual General Meeting. The AGM will be conducted on September 17, 2026, via video conference and other audio-visual means,...
Sai Life Sciences sets virtual 27th AGM, outlines e-voting schedule
Sai Life Sciences Ltd. has scheduled its 27th Annual General Meeting for September 17, 2026, at 10:30 a.m. IST, to be conducted via video conferencing and other audio-visual means in line with guidance from the Ministry of Corporate Affairs and SEBI....
Sai Life Sciences Sets September 17 Virtual AGM, Publishes E-Voting Details
Sai Life Sciences Limited has scheduled its 27th Annual General Meeting for September 17, 2026, at 10:30 a.m. India time, to be conducted via video conference and other audio-visual means in line with provisions of the Companies Act and SEBI listing...
Sai Life Sciences Allots 18,700 Shares Under ESOP 2008
Sai Life Sciences has allotted 18,700 fully paid-up equity shares with a face value of Rs.1 each under its Employees Stock Option Plan 2008, following board approval at a meeting on 6 August 2026. The shares, issued in dematerialized form and listed...
Sai Life Sciences Posts Solid June-Quarter Results After Board Approval
Sai Life Sciences reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following approval by its board of directors at a meeting on August 6. The filing shows continued revenue generation and profi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 11, 2026